Agenus’ NEST Phase 2 Results Published In Clinical Cancer Research, No Colorectal Cancer Recurrences Observed At Updated Median Follow-Up Of 32.2 Months In NEST-1 And 23.5 Months In NEST-2 In pMMR/MSS Tumors, Neoadjuvant BOT+BAL Achieved 59% Pathologic Response, Including 41% Major Pathologic Response And 32% Pathologic Complete Response
No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major
Agenus tested a cancer medicine combo on patients, and the results showed the treatment worked well—patients didn't get sick again, and tumors shrank a lot. When a company's medicine shows it actually helps people in tests, that's a signal the company might be moving forward, so investors watch to see if it could become a real medicine someday.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.